The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
people have come in been randomized to four weekly injections of this apoa1 containing recombinant particle which is very effective at promoting cholesterol leaflux based on all the work that's been done with the idea being that this may directly impact the plaque and impact on cardiovascular events
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
this concept of promoting the efflux and reverse cholesterol transport pathway is being tested with another intervention called CSL 112 it's a form of apoa1 that's been complexed with lipids in a so-called recombinant HDL particle is being tested for impact on cardiovascular outcomes in the setting of acute coronary syndromes